Albany Molecular Research (AMRI)
Albany Molecular Research Cash Financing TTM: -6.214M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AMRI Cash Financing TTM Rankings
| Overall | 43rd percentile | 2313 of 4080 |
| Sector | 22nd percentile | 361 of 467 in Healthcare |
| Industry | 9th percentile | 130 of 143 in Biotechnology |
AMRI Cash Financing TTM Range, Past 5 Years
| Minimum | -18.61M | Dec 2008 |
| Maximum | 0.317M | Mar 2010 |
| Average | -7.568M |
About Cash From Financing (TTM)
The sum of the last four quarters of a company's cash flows from financing activities.
An item on a company's cash flow statement. Lists aggregate change in cash position resulting from financing activites. Includes the company's cash inflows and outflows from issuing cash dividends, issuing and selling stock, and adding or changing debt.
Learn More
You may also be interested in these AMRI related companies
AMRI News
Listen to $AMRI Q1 2012 earnings call - live at 10:00 AM, ondemand after - http://stks.co/3k43
about 18 days ago by earningscast
about 18 days ago by earningscast
I need all the ones that horizon Alerted recently that im currently stuck in way down $RCON $AMRI $NFC $SINO and more to go up a lot
about 23 days ago by epime7heus
about 23 days ago by epime7heus
AMRI Launches SMARTSOURCING™ For Contract Manufacturing and Research Services
Apr 30, 8:00AM PR Newswire
Apr 30, 8:00AM PR Newswire
AMRI Announces Development and Manufacturing Deal with Biota Holdings Limited
Apr 17, 8:00AM PR Newswire
Apr 17, 8:00AM PR Newswire
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
Apr 03, 8:01AM Benzinga
Apr 03, 8:01AM Benzinga
AMRI Hires Senior Manager to Oversee Facilities at Burlington Aseptic Fill Operations
Mar 27, 8:00AM PR Newswire
Mar 27, 8:00AM PR Newswire
Albany Molecular Research (AMRI) Reports Q4 Loss of $0.19; Guides Contract Revs
Feb 07, 8:05AM Street Insider
Feb 07, 8:05AM Street Insider
AMRI CFO to Present at UBS 22nd Annual Global Healthcare Services Conference
Feb 01, 8:00AM PR Newswire
Feb 01, 8:00AM PR Newswire
Albany Molecular (AMRI) Announces Workforce Reduction, to Cease Facility Lease; Updates on Expected Charges
Dec 22, 5:08PM Street Insider
Dec 22, 5:08PM Street Insider
Insider Cluster-Buying At $AMRI. 23,900 shares purchased. http://stks.co/1Xse
about 165 days ago by abubnic
about 165 days ago by abubnic
Sterne Agee reiterated its “Buy” rating on $AMRI with a price target of $7.00.
about 165 days ago by abubnic
about 165 days ago by abubnic
$AMRI $5.00 Hagen Steven R officer (VP Pharmaceutical Dev & Mfg) S 198 @ $4.84 amnt $958 proc'd ($32) 5/6/2011
about 381 days ago by canarionyc
about 381 days ago by canarionyc
$AMRI http://chart.ly/xvpba4r Closed above 50 day on high volume, 10% of float is short, MACD looks ready
about 405 days ago by Tr8r_x
about 405 days ago by Tr8r_x
$AMRI Hagen Steven R officer (VP Pharmaceutical Dev & Mfg) sold 2,000 @ $5.20 totl $10,400.00 2010-12-06
about 524 days ago by canarionyc
about 524 days ago by canarionyc
start swing long 1k $AMRI on long time coming trend reversal, looking for 6.3 stop 5.3
about 709 days ago by Assailed
about 709 days ago by Assailed
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMRI | 2.71 | -0.05 | -1.81% | 83.39M |
| AMRC | 11.07 | -0.15 | -1.34% | 289.15M |
| AMPL | 0.185 | +0.01 | +2.83% | 10.38M |
| ALVR | 0.49 | +0.03 | +6.52% | 28.41M |
| ALV | 57.16 | -0.25 | -0.44% | 5.116B |
| ALU | 1.67 | +0.07 | +4.38% | 3.883B |
| ALTR | 34.42 | +0.66 | +1.96% | 11.11B |
| ALTI | 0.66 | +0.00 | +0.00% | 45.84M |
| ALTH | 1.80 | +0.00 | +0.00% | 192.53M |
| ALTE | 22.72 | -0.28 | -1.22% | 2.292B |
